- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
New dry eye treatment gains IND acceptance
Parion Sciences has received acceptance from the FDA of its Investigational New Drug (IND) application for the company’s treatment for dry eye disease, P-321 ophthalmic solution.
Durham, NC-Parion Sciences has received acceptance from the FDA of its Investigational New Drug (IND) application for the company’s treatment for dry eye disease, P-321 ophthalmic solution.
Preclinical data that supported the approval was presented at the Association for Research in Vision and Ophthalmology’s annual meeting earlier this month.
“The FDA’s acceptance of our IND marks an important milestone in our ophthalmology program, as we advance (the treatment) into a phase I/IIa clinical trial in subjects with dry eye,” said Paul Boucher, president of Parion Sciences. “The potential and long-lasting effect of (the treatment) to hydrate the ocular surface could provide a needed relief to patients suffering from dry eye.”
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
